|   From the Trenches

Navigating Change: Observations from the Talent side of Professional Change

Like many of you, I’m a consumer of biotech industry news. Multiple times of day I scour BioCentury, STAT, Endpoints, Fierce Biotech and LinkedIn to track the scientific landscape, company events, and people updates. During the height of the pandemic, these information sources fueled my confidence that vaccines were on the horizon and that our industry – biotech, pharma, and venture – was all the more pivotal. The 2020-21 news put a spotlight on the speed of innovation, the acceleration of company creation, and the ever-tightening competition for talent. It felt like an endless positive-loop of progress and hope and served as a fantastic motivation for my role as Talent Head at Atlas Venture. Despite the difficult life changes the pandemic created (quarantining, social distancing, remote work), the biotech industry raced forward with possibility, and the demand for talent created limitless opportunity for upward professional change.

By Andrea DiMella, VP and Head of Talent at Atlas Venture, as part of the From The Trenches feature of LifeSciVC

Read more.


  |   From the Trenches

Take the Hors D’oeuvres When They’re Passed And Other Life Lessons From An “Old” CEO

Our company recently launched out of stealth with a trade media campaign in the usual outlets, which felt great until one article title included an unfortunate grammatical error.

By Natalie Holles, CEO of Third Harmonic Bio, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   In the News

To spend less on health care, invest more in medicines

The conventional wisdom that we need to reduce spending on prescription drugs is all wrong. In an ideal health care system, we’d spend more on drugs, not less.

Read more.


  |   LifeSciVC

Biotech’s January Chill: Big Drop In New Startups

While the pace of startup formation in biotech has been accelerating over the past decade, early signs suggest the malaise in the markets is finding its way back into the venture creation ecosystem.

Read more.


  |   From the Trenches

Collaborating with Patient Advocacy Groups to Advance Rare Disease Awareness and Support

Over my many years in the biopharma industry, working across disease areas, including orphan indications, I have learned that to impact patients’ lives credibly and meaningfully, we must raise awareness about the conditions we are attempting to treat. One of the most effective ways is to engage with patient advocacy groups who are more closely connected to patients and caregivers and have a deep knowledge of their needs. Access to patient groups is particularly important for work related to rare disease indications given the challenging combination of urgent patient needs, and limited resources and knowledge.

By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC.

Read more.